AMGN vs NVS
Amgen and Novartis AG, both Healthcare
Novartis AG is the larger company at $275B against $226B. On trailing earnings NVS is the cheaper of the two at a P/E of 21.3 against 25.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year AMGN returned +49% against +20% for NVS. The RyuScore puts NVS ahead, 75 against 63 out of 100.
| Figure | AMGN | NVS |
|---|---|---|
| Last close | $418 | $144 |
| Market cap | $226B | $275B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 25.9 | 21.3 |
| Dividend yield | 2.3% | n/a |
| 1-year return | +49% | +20% |
| 5-year return | +125% | +104% |
| RyuScoresector-relative, 1–10 | 63/100 | 75/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Novartis AG
Revenue of $27B in H2 2025, net income $6.3B.
Open these two in the interactive comparison to add more names, change the period or see the correlation.